Patients with bipolar disorder have one of the highest rates of nicotine dependence and one
of the lowest quit rates. Varenicline has been shown in previous trials to be effective for
smoking cessation, but has not been studied in subjects with bipolar disorder. This 12-week
open label trial will be conducted to assess the feasibility, acceptability, and safety of
varenicline in bipolar depressed smokers, given in addition to the subject's primary
treatment for bipolar disorder. The primary study hypothesis was that the abstinence rate for
bipolar depressed patients will be 50%.